BridgeMD
New treatment option for Status Epilepticus
Official title Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis
ClinicalTrials.gov ID: NCT04421846
What this study is testing
- What it's testing
- COLETTE is an interventional study for which blood, cerebrospinal fluid and post-mortem tissues are collected in patients with status epilepticus or epilepsy associated to dysimmune encephalitis as well as in control patients, to better understand the pathophysiology of these severe epileptic disorders.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 2 and older
You may be able to join if
- Group 1:
- Patients aged 2 years or above, with status epilepticus.
- Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
- Patients or relatives have been informed and given free informed and written consent to participate
- Patients under legal protection (guardianship, curatorship) or not Group 2:
You likely can't join if
- Group 1:
- Women with known or clinically detected pregnancy.
- Patient deprived of liberty
- Patients with known neurodegenerative disease. Group 2:
- Women with known or clinically detected pregnancy.
- Patient deprived of liberty
See the full eligibility criteria
- Group 1:
- Patients aged 2 years or above, with status epilepticus.
- Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
- Patients or relatives have been informed and given free informed and written consent to participate
- Patients under legal protection (guardianship, curatorship) or not Group 2:
- Patients aged 2 years or above, with clinical signs of epilepsy associated to dysimmune encephalitis.
- Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
- Patients or relatives have been informed and given free informed and written consent to participate
- Patients under legal protection (guardianship, curatorship) or not Group 3:
- Patients aged 18 years or above, without status epilepticus and/or dysimmune encephalitis.
- Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
- Patients or relatives have been informed and given free informed and written consent to participate
- Patients under legal protection (guardianship, curatorship) or not
- Group 1:
- Women with known or clinically detected pregnancy.
- Patient deprived of liberty
- Patients with known neurodegenerative disease. Group 2:
- Women with known or clinically detected pregnancy.
- Patient deprived of liberty
- Patients have been already treated by corticoids or IgIV. Group 3:
- Women with known or clinically detected pregnancy.
- Patient deprived of liberty.
- Patients with status epilepticus.
- Patients with known neurodegenerative disease, brain tumor, severe head trauma, meningitis, subarachnoid hemorrhages, stroke.
The study team makes the final eligibility decision.
Where it's taking place
- Paris, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 2 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Paris, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.